Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Gilley, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goetz, C. G.
Right arrow Articles by Gilley, D.
NEUROLOGY 1988;38:1143
© 1988 American Academy of Neurology

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations

C. G. Goetz, MD, C. M. Tanner, MD, K. M. Shannon, MD, V. S. Carroll, MS, H. L. Klawans, MD, P. M. Carvey, PhD and D. Gilley

From the Department of Neurological Sciences, Rush-Presbyterian St. Luke's Medical Center, Chicago, IL.

Sixteen patients with advanced Parkinson's disease (PD) and motor fluctuations were evaluated throughout 12 months of open label therapy on CR4-Sinemet. Reduced dosage frequency and significant motor improvement with reduced fluctuation occurred and were maintained with CR4-Sinemet compared with baseline on Sinemet. In a double-blind protocol using CR4-Sinemet in 20 stable PD patients, CR4-Sinemet was given twice daily and compared with Sinemet given four times daily. Patients remained stable without improvement or deterioration when the long-acting drug was substituted at 50% frequency. Plasma levodopa levels with CR4-Sinemet were smoother than with Sinemet. Although some patients receiving CR4-Sinemet found they functioned more slowly in the morning, the easier dosing schedule and improved amount of "on" time in fluctuators suggest that this formulation may become increasingly useful in managing PD.

Address correspondence and reprint requests to Dr. Goetz, Department of Neurological Sciences, Rush-Presbyterian-St. Luke's Medical Center, 1653 West Congress Parkway, Chicago, IL 60612–3864.

Received September 14, 1987. Accepted for publication in final form December 7, 1987.




This article has been cited by other articles:


Home page
 Arch NeurolHome page
C. G. Goetz and V. K. Hinson
Therapies for Movement Disorders
Arch Neurol, May 1, 2002; 59(5): 699 - 702.
[Full Text] [PDF]

Home page
 J Child NeurolHome page
M. R. Pranzatelli
Topical Review: Antidyskinetic Drug Therapy for Pediatric Movement Disorders
J Child Neurol, September 1, 1996; 11(5): 355 - 369.
[Abstract] [PDF]

Home page
 Neurorehabil Neural RepairHome page
R. B. Wright, J. L. Costa, M. Brandabur, S. Junger, A. McRae, and P. M. Carvey
A Variant of Akinetic Mutism: Biochemical and Physiological Studies During Successful Withdrawal from Sinemet
Neurorehabil Neural Repair, January 1, 1990; 4(3): 163 - 167.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1988 by AAN Enterprises, Inc.